Key TakeawaysJohnson & Johnson (JNJ) announced a 100% overall response rate (ORR) for its combination therapy of Tecvayli and Darzalex in newly diagnosed multiple myeloma patients, marking a significant advancement in cancer treatment.The promising results from the Phase 1/2 study suggest a potential new frontline treatment option for multiple myeloma, a difficult-to-treat blood cancer.Separately, a report from MSNBC alleges that former high-ranking official Homan sought a $50,000 payment from individuals b ...